|
|
Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics. 2012. Zhang Wei, et al. [Article:22256871@PubMed] |
|
|
Drug- and non-drug-associated QT interval prolongation. British journal of clinical pharmacology. 2010. van Noord Charlotte, et al. [Article:20642543@PubMed] |
|
|
Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clinical pharmacology and therapeutics. 2010. Morganroth J, et al. [Article:20220748@PubMed] |
|
|
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. [Article:20150828@PubMed] |
|
|
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. [Article:21079043@PubMed] |
|
|
Arrhythmia pharmacogenomics: methodological considerations. Current pharmaceutical design. 2009. Roden Dan M, et al. [Article:19925424@PubMed] |
|
|
Common candidate gene variants are associated with QT interval duration in the general population. Journal of internal medicine. 2009. Marjamaa A, et al. [Article:19019189@PubMed] |
|
|
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nature genetics. 2009. Newton-Cheh Christopher, et al. [Article:19305408@PubMed] |
|
|
Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations. BMC medical genetics. 2008. Zhang Xianqin, et al. [Article:18808722@PubMed] |
|
|
hERG potassium channels and the structural basis of drug-induced arrhythmias. Chemical research in toxicology. 2008. Mitcheson John S. [Article:18447395@PubMed] |
|
|
Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. Current medicinal chemistry. 2008. Drago Antonio, et al. [Article:18855674@PubMed] |
|
|
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). European heart journal. 2008. Sinner Moritz F, et al. [Article:18222980@PubMed] |
|
|
Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. Journal of pharmacological sciences. 2008. Sakaguchi Tomoko, et al. [Article:19057127@PubMed] |
|
|
Molecular determinants of hERG channel block by terfenadine and cisapride. Journal of pharmacological sciences. 2008. Kamiya Kaichiro, et al. [Article:18987434@PubMed] |
|
|
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Molecular pharmacology. 2008. Perrin Mark J, et al. [Article:18701618@PubMed] |
|
|
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity. Proceedings of the National Academy of Sciences of the United States of America. 2008. Gentile Saverio, et al. [Article:18791070@PubMed] |
|
|
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochemical pharmacology. 2007. Duncan R S, et al. [Article:17560554@PubMed] |
|
|
Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation. 2007. Newton-Cheh Christopher, et al. [Article:17709632@PubMed] |
|
|
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical pharmacology and therapeutics. 2007. Eap C B, et al. [Article:17329992@PubMed] |
|
|
Drug-induced long QT and torsade de pointes: recent advances. Current opinion in cardiology. 2007. Kannankeril Prince J, et al. [Article:17143043@PubMed] |
|
|
Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. European journal of human genetics : EJHG. 2007. Gouas L, et al. [Article:17534376@PubMed] |
|
|
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenetics and genomics. 2007. Spraggs Colin, et al. [Article:18004211@PubMed] |
|
|
HERG is protected from pharmacological block by alpha-1,2-glucosyltransferase function. The Journal of biological chemistry. 2007. Nakajima Tadashi, et al. [Article:17189275@PubMed] |
|
|
hERG potassium channels and cardiac arrhythmia. Nature. 2006. Sanguinetti Michael C, et al. [Article:16554806@PubMed] |
|
|
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. The Journal of pharmacology and experimental therapeutics. 2006. Katchman Alexander N, et al. [Article:16278312@PubMed] |
|
|
Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. The Journal of pharmacology and experimental therapeutics. 2006. Wisialowski Todd, et al. [Article:16614168@PubMed] |
|
|
Pentamidine reduces hERG expression to prolong the QT interval. British journal of pharmacology. 2005. Cordes Jason S, et al. [Article:15711592@PubMed] |
|
|
Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circulation research. 2005. Pfeufer Arne, et al. [Article:15746444@PubMed] |
|
|
The phenothiazine drugs inhibit hERG potassium channels. Drug and chemical toxicology. 2005. Kim Ki-Suk, et al. [Article:16051556@PubMed] |
|
|
Predictive in silico modeling for hERG channel blockers. Drug discovery today. 2005. Aronov Alex M. [Article:15718164@PubMed] |
|
|
Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart rhythm : the official journal of the Heart Rhythm Society. 2005. Fitzgerald Patrick T, et al. [Article:16253929@PubMed] |
|
|
Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart rhythm : the official journal of the Heart Rhythm Society. 2005. Kannankeril Prince J, et al. [Article:15851285@PubMed] |
|
|
Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. American journal of physiology. Heart and circulatory physiology. 2004. Anson Blake D, et al. [Article:14975928@PubMed] |
|
|
Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. Clinical science (London, England : 1979). 2004. Hayashi Kenshi, et al. [Article:15043509@PubMed] |
|
|
Drug-induced torsades de pointes and implications for drug development. Journal of cardiovascular electrophysiology. 2004. Fenichel Robert R, et al. [Article:15090000@PubMed] |
|
|
Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. Journal of molecular and cellular cardiology. 2004. Sun Zhuoqian, et al. [Article:15522280@PubMed] |
|
|
Mechanisms of arsenic-induced prolongation of cardiac repolarization. Molecular pharmacology. 2004. Ficker Eckhard, et al. [Article:15213294@PubMed] |
|
|
Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn-Schmiedeberg's archives of pharmacology. 2004. Zitron Edgar, et al. [Article:15322737@PubMed] |
|
|
Drug-induced prolongation of the QT interval. The New England journal of medicine. 2004. Roden Dan M. [Article:14999113@PubMed] |
|
|
QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. American journal of therapeutics. 2003. Cubeddu Luigi X. [Article:14624285@PubMed] |
|
|
Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide. Biochemical and biophysical research communications. 2003. Ridley John M, et al. [Article:12804575@PubMed] |
|
|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. Journal of medicinal chemistry. 2003. Pearlstein Robert, et al. [Article:12747773@PubMed] |
|
|
The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003. Kupershmidt Sabina, et al. [Article:14525949@PubMed] |
|
|
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002. Yang Ping, et al. [Article:11997281@PubMed] |
|
|
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European journal of pharmacology. 2002. Kongsamut Sathapana, et al. [Article:12176106@PubMed] |
|
|
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. The Journal of pharmacology and experimental therapeutics. 2002. Thomas Dierk, et al. [Article:11805215@PubMed] |
|
|
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. European journal of pharmacology. 2001. Finlayson K, et al. [Article:11698075@PubMed] |
|
|
A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2000. Mitcheson J S, et al. [Article:11005845@PubMed] |
|
|
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999. Abbott G W, et al. [Article:10219239@PubMed] |
|
|
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation. 1999. Priori S G, et al. [Article:9950666@PubMed] |
|
|
Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Journal of cardiovascular electrophysiology. 1999. Zhou Z, et al. [Article:10376921@PubMed] |
|
|
Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. The American journal of physiology. 1997. Mohammad S, et al. [Article:9374794@PubMed] |
|
|
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation. 1996. Roden D M, et al. [Article:8873679@PubMed] |
|
|
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995. Sanguinetti M C, et al. [Article:7736582@PubMed] |
|
|
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995. Schwartz P J, et al. [Article:8521555@PubMed] |